(Q39325230)

English

Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

toll-like receptor

0 references

author name string

Erina Koga-Yamakawa

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Simon J Dovedi

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Masashi Murata

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Hiroyuki Matsui

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Andrew J Leishman

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

John Bell

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Douglas Ferguson

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Simon P Heaton

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Toshihiro Oki

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Hideyuki Tomizawa

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ash Bahl

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Haruo Takaku

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Robert W Wilkinson

13

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Hideyuki Harada

14

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

11 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

132

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

580-590

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Toll-like receptors--sentries in the B-cell response

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Immunosuppressive networks in the tumour environment and their therapeutic relevance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

The role of the kinases RIP1 and RIP3 in TNF-induced necrosis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

TLR7 and TLR8 as targets in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27691

21 January 2018

Identifiers

10.1002/IJC.27691

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39325230&oldid=1820202705"